Oppenheimer Maintains Perform on Legend Biotech, Lowers Price Target to $25

Benzinga · 2d ago
Oppenheimer analyst Kostas Biliouris maintains Legend Biotech (NASDAQ:LEGN) with a Perform and lowers the price target from $40 to $25.